Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
0.3623
+0.0021 (0.58%)
Aug 28, 2026, 12:17 PM EDT - Market open
Silexion Therapeutics Employees
As of December 31, 2025, Silexion Therapeutics had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$997,000
Market Cap
2.01M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - | 13 | 1 |
| Dec 31, 2024 | 14 | - | - | 11 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Scinai Immunotherapeutics | 45 |
| Virax Biolabs Group | 26 |
| Curis | 24 |
| Decoy Therapeutics | 11 |
| CDT Equity | 4 |
| Oragenics | 3 |
| Bone Biologics | 2 |
| Propanc Biopharma | 2 |
SLXN News
- 11 days ago - Silexion Therapeutics prices $2.5M public offering at $0.65 per share - TheFly
- 14 days ago - Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 16 days ago - Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - GlobeNewsWire
- 20 days ago - Silexion Therapeutics files to sell ordinary shares, warrants, no amount given - TheFly
- 24 days ago - Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - GlobeNewsWire
- 4 weeks ago - Silexion Therapeutics downgraded at Maxim on delisting and dilution risk - TheFly
- 4 weeks ago - Silexion Therapeutics downgraded to Hold from Buy at Maxim - TheFly
- 4 weeks ago - Silexion Therapeutics initiates SIL204 trial - TheFly